{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:38Z","timestamp":1786120298030,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/crd.0b013e31822e9ba3","type":"journal-article","created":{"date-parts":[[2011,10,6]],"date-time":"2011-10-06T04:50:49Z","timestamp":1317876649000},"page":"300-304","source":"Crossref","is-referenced-by-count":17,"title":["Azilsartan"],"prefix":"10.1097","volume":"19","author":[{"given":"Sum","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210203","first-page":"e46","article-title":"Heart disease and stroke statistics\u20142010 update: a report from the American Heart Association.","volume":"121","author":"Lloyd-Jones","year":"2010","journal-title":"Circulation"},{"key":"R2-6-20210203","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"R3-6-20210203","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs.","volume":"356","author":"Neal","year":"2000","journal-title":"Lancet"},{"issue":"suppl 1","key":"R4-6-20210203","first-page":"S4","article-title":"Executive summary: standards of medical care in diabetes\u20142011.","volume":"34","year":"2011","journal-title":"Diabetes Care"},{"key":"R5-6-20210203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.ajkd.2004.03.003","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R6-6-20210203","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2010.650","article-title":"US trends in prevalence, awareness, treatment, and control of hypertension, 1988\u20132008.","volume":"303","author":"Egan","year":"2010","journal-title":"JAMA"},{"key":"R7-6-20210203","first-page":"22","article-title":"Use of angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.","volume":"36","author":"Munger","year":"2001","journal-title":"P T"},{"key":"R8-6-20210203","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol.","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"R9-6-20210203","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial.","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"R10-6-20210203","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure.","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"R11-6-20210203","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM\u2013Added trial.","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"R12-6-20210203","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM\u2013Alternative trial.","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"R13-6-20210203","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R14-6-20210203","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"R15-6-20210203","article-title":"Product Information: Edarbi oral tablets, azilsartan medoxomil oral tablets.","year":"2011"},{"key":"R16-6-20210203","first-page":"139","article-title":"Dipiro's Pharmacotherapy: A Pathophysiologic Approach. 7th ed.","author":"Saseen","year":"2008"},{"key":"R17-6-20210203","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.110.163402","article-title":"Effects of the Angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.","volume":"57","author":"White","year":"2011","journal-title":"Hypertension"},{"key":"R18-6-20210203","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1751-7176.2010.00425.x","article-title":"The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.","volume":"13","author":"Bakris","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R23-6-20210203","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/bmj.39548.738368.BE","article-title":"Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials.","volume":"336","author":"Turnbull","year":"2008","journal-title":"BMJ"},{"key":"R24-6-20210203","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/00004872-200306000-00002","article-title":"Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.","volume":"21","author":"Staessen","year":"2003","journal-title":"J Hypertens"},{"key":"R25-6-20210203","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jash.2007.05.003","article-title":"Angiotensin receptor blockers vs. angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elderly patients: a population based cohort study (UMPIRE study results).","volume":"1","author":"Verma","year":"2007","journal-title":"J Am Soc Hypertens"},{"key":"R26-6-20210203","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","article-title":"Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system.","volume":"25","author":"Turnbull","year":"2007","journal-title":"J Hypertens"},{"key":"R27-6-20210203","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial\u2014the Losartan Heart Failure Survival Study ELITE II.","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"R28-6-20210203","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"R29-6-20210203","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"R30-6-20210203","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events.","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00045415-201111000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:23:54Z","timestamp":1786047834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045415-201111000-00006"}},"subtitle":["A Newly Approved Angiotensin II Receptor Blocker"],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0b013e31822e9ba3","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}